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Background: The aim of this study was to investigate the characteristics and outcomes of patients receiving renal
replacement therapy for end-stage kidney disease (ESKD) secondary to haemolytic uraemic syndrome (HUS).
Methods: The study included all patients with ESKD who commenced renal replacement therapy in Australia and
New Zealand between 15/5/1963 and 31/12/2010, using data from the ANZDATA Registry. HUS ESKD patients were
compared with matched controls with an alternative primary renal disease using propensity scores based on age,
gender and treatment era.
Results: Of the 58422 patients included in the study, 241 (0.4%) had ESKD secondary to HUS. HUS ESKD was
independently associated with younger age, female gender and European race. Compared with matched controls,
HUS ESKD was not associated with mortality on renal replacement therapy (adjusted hazard ratio [HR] 1.14, 95% CI
0.87-1.50, p = 0.34) or dialysis (HR 1.34, 95% CI 0.93-1.93, p = 0.12), but did independently predict recovery of renal
function (HR 54.01, 95% CI 1.45-11.1, p = 0.008). 130 (54%) HUS patients received 166 renal allografts. Overall renal
allograft survival rates were significantly lower for patients with HUS ESKD at 1 year (73% vs 91%), 5 years (62% vs
85%) and 10 years (49% vs 73%). HUS ESKD was an independent predictor of renal allograft failure (HR 2.59, 95% CI
1.70-3.95, p < 0.001). Sixteen (12%) HUS patients experienced failure of 22 renal allografts due to recurrent HUS. HUS
ESKD was not independently associated with the risk of death following renal transplantation (HR 0.92, 95% CI
0.35-2.44, p = 0.87).
Conclusions: HUS is an uncommon cause of ESKD, which is associated with comparable patient survival on dialysis,
an increased probability of renal function recovery, comparable patient survival post-renal transplant and a
heightened risk of renal transplant graft failure compared with matched ESKD controls.
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Haemolytic uraemic syndrome (HUS) is a condition
characterised by thrombotic microangiopathy, throm-
bocytopenia, microangiopathic hemolytic anemia, renal
dysfunction, neurologic deficits and sometimes dysfunc-
tion of other organs, such as heart, lungs, gastrointestinal
tract and pancreas [1,2]. When neurologic dysfunction
predominates, the disease is often referred to as throm-
botic thrombocytopenic purpura (TTP). HUS is typically
caused by Shiga-like toxin-producing bacteria, particularly
E. coli O157:H7 [3], or non-enteropathic infections (such
as with S. pneumoniae) [4]. Approximately 10% of HUS
cases are not associated with diarrhoea or shiga toxin-
producing E. coli and are referred to as atypical HUS [1,5].
This heterogeneous disorder may be either familial or
sporadic and can be caused or triggered by complement
regulatory protein mutations (50%), complement factor H
autoantibodies (6-10%), human immunodeficiency virus
infection, autoimmune disorders, cardiovascular surgery,
transplantation, disseminated malignancy, pregnancy and
certain drugs (including calcineurin inhibitors, muromo-
nab-CD3, valacicylovir, clopidogrel, ticlopidine, bleomycin,
gemcitabine and cisplatin) [1,2,6-8].
The worldwide incidence of HUS is reported to be 1–2
cases per 100,000 people per year [1,9]. Progression to
end-stage kidney disease (ESKD) occurs in 3% of patients
with diarrhoea-associated HUS [10], 50% of atypical HUS
cases [1] and 50-80% of familial atypical HUS cases [1].
Previous studies of the predictors, course and outcomes of
ESKD patients with HUS have been limited, often
restricted to single centre investigations and primarily fo-
cused on renal transplantation rather than dialysis
[1,2,11,12]. To date, there has not been a comprehensive,
multi-centre examination of ESKD secondary to HUS.
The aim of the present study was to investigate the char-
acteristics, treatments and outcomes of all cases of ESKD
due to HUS in the Australian and New Zealand dialysis
populations, using data from the Australia and New
Zealand Dialysis and Transplant (ANZDATA) registry.Methods
Patient population
The cohort study included all patients with ESKD enrolled
in the ANZDATA registry, who commenced renal replace-
ment therapy between 15 May 1963 and 31 December
2010. All patients entered into the ANZDATA registry
were considered by their treating nephrologists to have
ESKD and therefore thought to require long-term renal
replacement therapy at the time they were enrolled. The
data collected included demographic data, cause of pri-
mary renal disease, renal replacement therapy (RRT) dates
and modalities, smoking status, body mass index (BMI),
late referral (defined as commencement of dialysis within3 months of referral to a nephrologist), serum creatinine
concentration at dialysis commencement, comorbidities
(hypertension, chronic lung disease, cardiovascular disease
and diabetes mellitus) and outcomes (patient, technique
and renal allograft survival). Body mass index (BMI) was
calculated from weight/height2 and expressed in kg/m2.
Patients with a primary renal diagnosis of HUS were com-
pared with the remainder of the cohort with an alternative
primary renal diagnosis (non-HUS). For each of the RRT,
dialysis and renal transplant cohorts, HUS ESKD patients
were matched with controls with alternative causes of
ESKD by propensity score matching [13]. The propensity
score was calculated by using multivariable logistic regres-
sion, in which HUS was the outcome variable and age,
gender and treatment era were the independent variables.
The derived propensity scores were then used to match
HUS patients with controls in a 1:1 ratio. Survival analyses
were restricted to HUS ESKD patients and matched con-
trols. Ethical approval for the use of registry data was
obtained from the Princess Alexandra Hospital Human
Research Ethics Committee.
The primary outcomes were patient survival on
renal replacement therapy (censored for renal func-
tion recovery, loss to follow-up and end of study),
patient survival on dialysis (censored for renal func-
tion recovery, loss to follow-up, renal transplantation
and end of study), time from dialysis commencement
to recovery of dialysis-independent renal function
(censored for death, loss to follow-up, renal trans-
plantation and end of study), renal transplant patient
survival (censored for allograft failure, loss to follow-
up and end of study) and renal allograft survival
(censored for death, loss to follow-up and end of
study). Recovery of dialysis-independent renal func-
tion was considered to have occurred if the treating
renal unit had recorded that the patient had recov-
ered renal function and completed dialysis therapy.
The onset of recovery was defined as the date of the
last dialysis treatment.Statistical analysis
Results were expressed as frequencies and percentages for
categorical variables, mean ± standard deviation for con-
tinuous normally distributed variables, and median [inter-
quartile range; IQR] for continuous variables that were not
normally distributed. Dichotomous and categorical data
were compared using chi-square tests. Continuous nor-
mally distributed data were compared using two tailed
unpaired t-tests. Continuous non-normally distributed
data were compared using Mann–Whitney tests. The
independent predictors of HUS ESKD were assessed by
multivariate logistic regression analysis. Time to event
analyses were evaluated by Kaplan Meier and multivariate
Table 1 Characteristics of all patients with ESKD secondary to HUS or other causes in Australia and New Zealand
1963–2010, before and after matching for age, gender and RRT era
Before matching After matching
Characteristic HUS ESKD (n = 241) Other ESKD (n = 58181) P value Other ESKD Control (n = 241) P value
Age 33.1 ± 21.8 54.2 ± 17.3 <0.001 33.1 ± 21.7 1.00
Age category <0.001 1.00
0-9 years 43 (18%) 529 (1%) 43 (18%)
10-19 years 28 (12%) 1607 (3%) 28 (12%)
20-29 years 46 (19%) 3978 (7%) 46 (19%)
30-39 years 32 (13%) 5772 (10%) 32 (13%)
40-49 years 31 (13%) 9122 (16%) 31 (13%)
50-59 years 25 (10%) 12339 (21%) 25 (10%)
60-69 years 21 (9%) 12866 (22%) 21 (9%)
70-79 years 13 (5%) 9741 (17%) 13 (5%)
80+ years 2 (1%) 2327 (4%) 2 (1%)
Male gender 90 (37%) 33913 (58%) <0.001 90 (37%) 1.00
Racial origin <0.001 <0.001
European 217 (90%) 45368 (78%) 170 (71%)
ATSI 4 (2%) 3484 (6%) 22 (9%)
MPI 8 (3%) 5106 (9%) 24 (10%)
Asian 6 (3%) 2478 (4%) 9 (4%)
Other 6 (3%) 1745 (3%) 16 (7%)
RRT era 0.17 1.00
1963-1975 13 (5%) 2821 (5%) 12 (5%)
1976-1985 36 (15%) 6505 (11%) 36 (15%)
1986-1995 44 (18%) 12119 (21%) 45 (19%)
1996-2000 50 (21%) 9811 (17%) 49 (20%)
2001-2005 44 (18%) 12357 (21%) 45 (19%)
2006-2010 54 (22%) 14568 (25%) 54 (22%)
Ever smoked <0.001 0.85
Current 28 (12%) 6138 (11%) 31 (13%)
Former 42 (17%) 17713 (30%) 48 (20%)
Never 130 (54%) 22398 (39%) 122 (51%)
Missing 41 (17%) 11932 (21%) 40 (17%)
Hypertension <0.001 0.98
Yes 89 (37%) 24464 (42%) 87 (36%)
No 37 (15%) 4519 (8%) 38 (16%)
Missing 115 (48%) 29198 (50%) 116 (48%)
Diabetes mellitus <0.001 <0.001
Yes 8 (3%) 17874 (31%) 51 (21%)
No 201 (83%) 31796 (55%) 163 (68%)
Missing 32 (13%) 8511 (15%) 27 (11%)
Chronic lung disease 0.009 0.47
Yes 16 (7%) 7139 (12%) 22 (9%)
No 190 (79%) 41125 (71%) 190 (79%)
Missing 35 (15%) 9917 (17%) 29 (12%)
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Table 1 Characteristics of all patients with ESKD secondary to HUS or other causes in Australia and New Zealand
1963–2010, before and after matching for age, gender and RRT era (Continued)
Coronary artery disease <0.001 0.13
Yes 22 (9%) 17613(30%) 36 (15%)
No 184 (76%) 30768 (53%) 176 (7%)
Missing 35 (15%) 9800 (17%) 29 (12%)
Peripheral vascular disease <0.001 0.04
Yes 15 (6%) 11440 (20%) 31 (13%)
No 191 (79%) 36823 (63%) 181 (75%)
Missing 35 (15%) 9918 (17%) 29 (12%)
Cerebrovascular disease 0.01 0.38
Yes 14 (6%) 6540 (11%) 9 (4%)
No 192 (80%) 41742 (72%) 204 (84%)
Missing 35 (15%) 9899 (17%) 29 (12%)
BMI (kg/m2) 22.7 ± 6.2 26.6 ± 6.3 <0.001 24.5 ± 7.7 0.02
Late referral <0.001 <0.001
Yes 88 (37%) 9304 (16%) 34 (14%)
No 86 (36%) 33773 (58%) 156 (65%)
Missing 67 (28%) 15104 (26%) 51 (21%)
Renal Biopsy <0.001 <0.001
Yes 89 (37%) 16019 (28%) 85 (35%)
No 61 (25%) 29135 (50%) 117 (49%)
Miss 91 (38%) 13027 (22%) 39 (16%)
First RRT 0.46 0.02
Haemodialysis 163 (68%) 39135 (67%) 134 (56%)
Peritoneal dialysis 69 (29%) 17570 (30%) 92 (38%)
Renal Transplant 9 (4%) 1476 (3%) 15 (6%)
RRT duration (years) 4.7 [1.6-11.8] 3.8 [1.6-8.3] 0.03 6.4 [2.3-14.3] 0.03
Abbreviations: ATSI Aboriginal and Torres Strait Islander, BMI Body mass index, MPI Maori and Pacific Islander, RRT Renal replacement therapy.
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included in the model for the entire cohort were age,
gender, racial origin, ESKD cause (HUS or non-HUS), and
dialysis era (as well as donor type for renal transplant
analyses). In light of the possibility of informative censoring
due to differential transplantation rates and renal function
recovery rates between patients with and without HUS,
multivariate competing-risks regression was also performed
for dialysis patient survival analyses [14-16]. A supplemen-
tary, fully adjusted analysis was also conducted using a con-
temporary cohort (1996–2010), in whom data were
available on BMI, smoking status, history of chronic lung
disease, cerebrovascular disease, ischaemic heart disease,
diabetes mellitus, peripheral vascular disease and late refer-
ral. Data were analysed using the software package PASW
Statistics for Windows release 18.0 (SPSS Inc., North
Sydney, Australia) and Stata/SE version 12.0 (StataCorp.
CollegeStation, TX). P values less than 0.05 were consid-
ered statistically significant.Results
Patient characteristics
Between 15 May 1963 and 31 December 2010, 58422
individuals started RRT for ESKD. Of these, 241 (0.4%) had
ESKD secondary to HUS, whilst 58181 (99.6%) had ESKD
due to other causes. The baseline characteristics of the two
groups before and after matching are displayed in Table 1.
Using multivariable logistic regression analysis, ESKD
secondary to HUS was significantly and independently
associated with younger age (p < 0.001), female gender
(p < 0.001) and later dialysis era compared with other
forms of ESKD (Table 2). A lower probability of HUS
ESKD was observed in patients with Asian racial origin
(p = 0.03), Aboriginal and Torres Strait Islander (p = 0.001)
or Maori and Pacific Islander racial origin (p < 0.001).
In a supplementary analysis using a more contempor-
ary cohort (1996–2010) in which complete data were
available on comorbidities (n = 36884 including 148
patients with HUS ESKD), HUS ESKD was significantly
Table 2 Multivariable logistic regression analysis of
predictors of ESKD due to HUS, as opposed to other
causes of ESKD, in both the entire cohort (limited
covariate adjustment) and a contemporary cohort in







Age (per decade) 0.54 (0.50-0.57) 0.63 (0.57-0.69)
Male gender 0.40 (0.31-0.52) 0.40 (0.28-0.57)
Racial origin
European Reference Reference
ATSI 0.18 (0.07-0.47) 0.26 (0.08-0.85)
MPI 0.26 (0.13-0.52) 0.33 (0.14-0.77)
Asian 0.40 (0.18-0.92) 0.37 (0.15-0.91)








Ever smoked NA NS
Diabetes mellitus NA 0.13 (0.06-0.31)
Chronic lung disease NA NS
Coronary artery disease NA NS
Peripheral vascular disease NA NS
Cerebrovascular disease NA NS
BMI (kg/m2) NA NS
Late referral NA 3.72 (2.65-5.22)
Abbreviations: ATSI Aboriginal and Torres Strait Islander, BMI Body mass index,
MPI Maori and Pacific Islander, NA Not analysed due to incomplete data prior
to 1996, NS Not statistically significant, RRT Renal replacement therapy
Results are reported as adjusted odds ratio (95% CI).
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female gender (p < 0.001), late referral (p < 0.001) and lower
probability of diabetes mellitus (p < 0.001), Asian racial ori-
gin (p = 0.03), Aboriginal and Torres Strait Islander racial
origin (p = 0.03) or Maori and Pacific Islander racial origin
(p = 0.11).
Patient survival on renal replacement therapy
Overall, the survival of patients with HUS ESKD on RRT
(median 11.7 years, 95% CI 2.72-20.6 years) was compar-
able to that of matched controls (median 16.6 years, 95%
CI 11.4-21.7 years; log rank score 0.83, p = 0.36). Using
multivariable Cox proportional hazards model analysis,
HUS was not independently associated with mortality on
RRT (adjusted hazard ratio [HR] 1.14, 95% CI 0.87-1.50,
p = 0.34) in the entire cohort after adjusting for racialorigin (p = 0.22), and in the contemporary cohort (1996–
2010) (HR 1.11, 95% CI 0.68-1.80, p = 0.68) after adjusting
for racial origin (p = 0.55), chronic lung disease (HR 2.08
95% CI 1.17-3.69, p = 0.01), cerebrovascular disease (HR
2.03 95% CI 1.04-3.93, p = 0.04), ischaemic heart disease
(HR 2.13 95% CI 1.28-3.57, p = 0.004), diabetes mellitus
(HR 1.94 95% CI 1.06-3.55, p = 0.03), peripheral vascular
disease (p = 0.49), BMI (p = 0.52), late referral (p = 0.10)
and smoking status (p = 0.54).
Patient survival on dialysis
Death occurred in 68 (29%) HUS ESKD dialysis patients
and 62 (27%) matched dialysis controls (p = 0.54). The
causes of death were cardiac (31% vs 40%, respectively),
withdrawal from dialysis (21% vs 23%), infections (21% vs
10%), vascular (10% vs 10%), malignancy (3% vs 5%) and
other (15% vs 13%) (overall p = 0.58). Median patient sur-
vival on dialysis was comparable between HUS ESKD
(6.26 years, 95% CI 3.79-8.73 years) and matched controls
(6.24 years, 95% CI 4.59-7.89 years, log rank score 2.28,
p = 0.13) (Figure 1). Respective survival rates in the two
groups were 85% vs 94% at 1 year, 76% vs 87% at 2 years
and 56% vs 52% at 5 years. Using multivariable Cox propor-
tional hazards model analysis, HUS was not a predictor of
mortality on dialysis in the entire cohort (HR 1.35, 95% CI
0.93-1.96,p = 0.12) after adjusting for racial origin (p = 0.84),
or in the contemporary cohort (HR 0.91, 95% CI 0.53-1.56,
p = 0.73) after adjusting for racial origin (p = 0.67), chronic
lung disease (HR 2.24 95% CI 1.23-4.08, p = 0.008), ce-
rebrovascular disease (p = 0.25), ischaemic heart disease
(p = 0.32), diabetes mellitus (p = 0.23), peripheral vascular
disease (p = 0.16), BMI (p = 0.10), late referral (p = 0.15) and
smoking status (p = 0.26). HUS was not an independent
predictor of mortality when renal transplantation and renal
function recovery were treated as competing events in
competing-risk analysis (HR 1.34, 95% CI 0.93-1.93,
p = 0.12) after adjusting for racial origin.
When only patients with HUS dialysis were considered,
death on dialysis was predicted by older age (HR per dec-
ade 1.31, 95%CI 1.16-1.49, p < 0.001) and initiation of dialy-
sis in a later era (1996–2000 HR 0.34, 95% CI 0.12-0.97, p
= 0.045; 2001–2005 HR 0.22, 95% CI 0.07-0.67, p = 0.008;
2006–2010 HR 0.21, 95% CI 0.07-0.65, p = 0.007; 1963–
1975 reference), after adjusting for gender (p = 0.42) and
racial origin (p = 0.21).
Recovery of renal function
Recovery of dialysis-independent renal function occurred
in 21 (9%) HUS ESKD patients and 5 (2%) matched con-
trols (p = 0.001). Time to renal recovery was significantly
shorter in HUS ESKD (log rank score 11.2, p = 0.001).
Using multivariable Cox proportional hazards model ana-
lysis, HUS was a significant independent predictor of renal
function recovery in the entire cohort (HR 4.01, 95% CI
Figure 1 Kaplan-Meier survival curves for HUS dialysis ESKD
and matched control dialysis patients with other causes
of ESKD in Australian and New Zealand dialysis patients
1963–2010.
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(29%) HUS patients and 2 (40%) matched controls never
returned to renal replacement therapy by the end of the
study (31 December 2010). One (5%) HUS patient and 1
(20%) control died directly after recovery of renal
function. One (5%) HUS patient received a renal trans-
plant after 1.06 years. Thirteen (62%) HUS patients and 2
(40%) controls returned to dialysis after median periods of
0.94 years (interquartile range 0.19-5.54 years) and
0.19 years (interquartile range 0.06-0.31 years), respect-
ively (p = 0.17).
Renal transplant graft survival
A total of 130 (54%) patients with HUS ESKD received
166 renal allografts during the study period compared
with 19549 (34%) non-HUS ESKD patients who received
22773 renal allografts (p < 0.001). Excluding patients
undergoing pre-emptive renal transplantation (HUS ESKD
n = 9, non-HUS ESKD n = 1476), the median time from
dialysis commencement to first renal transplant was com-
parable for HUS patients (1.40 years, 95% interquartile
range 0.80-2.57) and non-HUS patients (1.44 years, 95%
CI 0.64-2.9, p = 0.9). The baseline characteristics of these
patients before and after matching are shown in Table 3.
Overall, the features of the two groups were similar, except
that HUS patients were younger and less likely to have
chronic lung disease, diabetes mellitus, coronary heart
disease, peripheral vascular disease, cerebral vascular
disease or hypertension. They were more likely to befemale, non-smoker, referred late to a renal unit, trans-
planted after 1996 and have received an allograft from a
living donor.
Renal allograft survival rates in patients with HUS
ESKD were generally inferior to those matched ESKD
controls, regardless of graft number (all, first or subse-
quent), donor type (living or deceased) and transplant
era. Mean death-censored first graft survivals for HUS
and matched ESKD controls were 12.0 years (95% CI
9.38-14.5 years; 10 year survival 49%) and 24.6 years
(95% CI 20.7-28.4 years, 10 year survival 73%, p < 0.001;
Figure 2), respectively. The respective values for first
grafts from deceased donors were 11.2 years (95% CI
7.69-14.7 years, 10 year survival 41%) and 21.6 years
(95% CI 17.7-25.5, 10 year survival 71%) (p < 0.001),
whilst those for first grafts from living donors were
12.3 years (95% CI 9.04-15.7 years, 10 year survival 59%)
and 26.8 years (95% CI 20.9-30.6 years, 10 year survival
76%) (p = 0.02). Using multivariable Cox proportional
hazards analysis, HUS was an independent predictor of
graft failure (HR 2.65, 95% CI 1.73-4.05, p < 0.001), after
adjusting for racial origin (p = 0.84) and donor type
(living versus deceased; p = 0.21).
When only HUS patients were considered, graft failure
was independently predicted by renal transplant era
(1963–1975 reference; 1976–1985 HR 0.29, 95% CI 0.08-
1.09, p = 0.07; 1986–1995 HR 0.24, 95% CI 0.06-0.91,
p = 0.04; 1996–2000 HR 0.17, 95% CI 0.04-0.66; 2001–
2005 HR 0.25, 95% CI 0.07-0.94, p = 0.04; 2006–2010 HR
0.02 95% CI 0.01-0.21, p < 0.001; overall p = 0.01), after
adjusting for age (p = 0.38), gender (p = 0.47), racial origin
(p = 0.93) and donor type (p = 0.51).
HUS recurrence in renal transplants
Sixteen (12%) HUS patients experienced failure of 22
renal allografts due to recurrent HUS (Table 4). The
median time between kidney transplantation and loss of
graft from recurrent HUS was 0.82 years (interquartile
range 0.18-3.10 years). Of the 16 HUS patients who lost
their first renal allograft from HUS, 8 underwent a
second kidney transplant and 3 (37.5%) lost these grafts
from recurrent HUS. Conversely, of the 51 HUS patients
who lost their first renal allograft for reasons other than
recurrent HUS, 23 underwent a second kidney trans-
plant and 3 (13%) lost these grafts from recurrent HUS.
Renal transplant patient survival
When first renal allografts were considered, the overall
survival of HUS patients (10-year survival 91%) was
comparable to that of matched ESKD controls (10 year
survival 93%, p = 0.96; Figure 3). HUS ESKD was not
independently associated with the risk of death following
renal transplantation (HR 1.01, 95% CI 0.38-2.69, p = 0.98)
after adjusting for donor type (living donor HR 0.16 95%
Table 3 Characteristics of all patients with ESKD secondary to HUS or other causes in Australia and New Zealand who
underwent renal transplantation during the period 1963–2010, before and after matching for age, gender and
transplant era
Before matching After matching
Characteristic HUS ESKD (n = 130) Other ESKD (n = 19549) P value Other ESKD Control (n = 130) P value
Age 25.2 ± 17.1 41.9 ± 14.8 <0.001 25.2 ± 17.0 0.98
Male gender 52 (40%) 11704 (60%) 0.001 52 (40%) 1.00
Racial origin 0.1 0.01
European 118 (91%) 16738 (86%) 104 (80%)
ATSI 1 (1%) 489 (3%) 3 (2%)
MPI 4 (3%) 812 (4%) 11 (9%)
Asian 1 (1%) 925 (5%) 9 (7%)
Other 6 (5%) 585 (3%) 3 (2%)
Transplant era 0.01 1.00
1963–1975 4(3%) 1939 (10%) 4 (3%)
1976–1985 23 (18%) 3448 (18%) 22 (17%)
1986–1995 22 (17%) 4595 (24%) 22 (17%)
1996–2000 26 (20%) 2667 (14%) 27 (21%)
2001–2005 24 (19%) 3150 (16%) 24 (19%)
2006-2009 31 (24%) 3750 (19%) 31 (24%)
Ever smoked <0.001 0.37
Current 10 (8%) 1560 (8%) 4 (3%)
Former 14 (11%) 3668 (19%) 15 (12%)
Never 82 (63%) 7788 (40%) 90 (69%)
Missing 24 (19%) 6533 (33%) 21 (16%)
Hypertension 0.009 0.35
Yes 54 (42%) 8562 (44%) 43 (33%)
No 23 (18%) 1898 (10%) 24 (19%)
Missing 53 (41%) 9089 (47%) 63 (49%)
Diabetes mellitus <0.001 0.007
Yes 1 (1%) 2098 (11%) 11 (9%)
No 113 (87%) 13435 (69%) 109 (84%)
Missing 16 (12%) 4016 (21%) 10 (8%)
Chronic lung disease 0.007 0.28
Yes 1 (1%) 581 (3%) 1 (1%)
No 111 (85%) 14333 (73%) 119 (92%)
Missing 18 (14%) 4637 (24%) 10 (8%)
Coronary artery disease 0.002 0.25
Yes 4 (3%) 1201 (6%) 3 (2%)
No 108 (83%) 13484(69%) 117 (90%)
Missing 18 (14%) 4864 (25%) 10 (8%)
Peripheral vascular disease 0.003 0.28
Yes 1 (1%) 703 (4%) 1 (1%)
No 111 (85%) 14137 (72%) 119 (92%)
Missing 18 (14%) 4709 (24%) 10 (8%)
Cerebrovascular disease 0.025 0.03
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Table 3 Characteristics of all patients with ESKD secondary to HUS or other causes in Australia and New Zealand who
underwent renal transplantation during the period 1963–2010, before and after matching for age, gender and
transplant era (Continued)
Yes 4 (3%) 391 (2%) 0 (0%)
No 108 (83%) 14525(74%) 120 (92%)
Missing 18 (14%) 4633 (24%) 10 (8%)
BMI (kg/m2) <0.001 0.86
Late referral 22.0 ± 5.9 24.7 ± 5.1 <0.001 21.8 ± 5.9 0.001
Yes 35 (27%) 1742 (9%) 15 (12%)
No 56 (43%) 10294 (53%) 84 (65%)
Missing 39 (30%) 7513 (38%) 31 (24%)
Donor type <0.001 1.00
Deceased 72 (55%) 14540 (74%) 72 (55%)
Living 58 (45%) 5009 (26%) 58 (45%)
Subsequent grafts 0.06 0.44
2 32 (19%) 2718 (12%) 22 (14%)
3 3 (2%) 440 (2%) 4 (3%)
4 1 (0%) 61 (0%) 0 (0%)
5 0 (0%) 5 (0%) 0 (0%)
Abbreviations: ATSI Aboriginal and Torres Strait Islander, BMI Body mass index, MPI Maori and Pacific Islander, RRT Renal replacement therapy.
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causes of death in the HUS (n = 7) and matched ESKD
control groups (n = 11) were generally comparable (overall
p = 0.21): cardiac (43% vs 9%, respectively), vascular (14%Figure 2 Kaplan-Meier death-censored first graft survival
curves for HUS ESKD and matched control patients with other
causes of ESKD undergoing renal transplantation in Australian
and New Zealand between 1963 and 2010.vs 36%), malignancy (29% vs 9%), infection (0% vs 27%)
and other (14% vs 18%).
Discussion
This retrospective, multi-centre, multi-country registry
analysis examined the outcomes of 241 patients with
HUS ESKD over 46 years. The principal findings were
that HUS ESKD was a rare cause of ESKD (0.4% of
cases) and was independently associated with younger
age, female gender and European racial origin. HUS
ESKD was also independently associated with a higher
probability of recovery of dialysis-independent renal
function and increased risks of renal allograft failure
compared with other causes of ESKD.
Very few studies have comprehensively examined the
predictors and outcomes of HUS ESKD, particularly in
dialysis populations. One previous investigation by the
Forum of ESKD Networks in the United States reported
199 cases of HUS ESKD [11]. In keeping with the findings
of the present study, the Forum observed a preponderance
of young, white, female patients. The respective propor-
tions of patients aged under 20 years, whites and females
were 30% vs 33%, 91% vs 88% and 63% vs 71%. These
findings are likely explained by the fact that HUS typically
affects children and younger adults, particularly females
[17,18]. The effect of ethnicity on HUS risk has not been
well studied, although African-Caribbean ancestry has
been observed as a risk factor [17].
Survival of HUS ESKD patients on dialysis has also
not been previously well described. The Forum of ESKD
Table 4 Causes of renal allograft failure in all patients with ESKD secondary to HUS or other causes who underwent
renal transplantation in Australia and New Zealand during the period 1963–2010
Characteristic HUS ESKD (n = 87) Other ESKD control (n = 44)
HUS 22 (25%) 0 (0%)
Hyperacute rejection 3 (3%) 0 (0%)
Acute rejection 13 (15%) 4 (9%)
Chronic allograft nephropathy 27 (31%) 19 (43%)
Renal artery thrombosis 5 (6%) 3 (7%)
Renal vein thrombosis 2 (2%) 1(2%)
Glomerulonephritis 1 (1%) 5 (11%)
Other 14 (16%) 12 (27%)
The differences between the groups were highly statistically significant (p = 0.002).
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patients was 77% at 3 years and somewhat better than
that seen in diabetic ESRD controls. However, the
authors noted that “this probably reflects in part the
lower average age of the patients.” In the present investi-
gation, the 3-year renal replacement therapy survival
rates of ESKD patients with HUS and matched controls
with other causes of ESKD were 74% and 80%, respect-
ively. Following adjustment for racial origin and comor-
bidities, patients with HUS ESKD had comparable
survival. This also applied to patients treated with
dialysis, even after adjusting for the competing risks of
renal transplantation and recovery of renal function. The
causes of death in the HUS patients were similar to
those of other ESKD patients and the limited numbers
did not permit useful, multivariable, sub-group analyses.Figure 3 Kaplan-Meier patient survival curves for HUS ESKD
and matched control patients with other causes of ESKD
undergoing first renal transplantation in Australian and New
Zealand between 1963 and 2010.Although the overall mortality rate of HUS ESKD
patients was comparable to that of matched controls,
HUS patients were also more likely to experience spon-
taneous recovery of dialysis-independent renal function.
A total of 21 (8.7%) HUS ESKD patients recovered renal
function, although 13 (62%) of these patients returned to
dialysis after a median period of 0.94 years. There have
been previous reports of renal recovery in patients
with HUS, even after relatively long periods on dialysis
[19-22]. Nissenson et al. [11] observed that 9% of
patients with ESKD secondary to HUS were able to dis-
continue dialysis. Moreover, our group has previously
found HUS to be an independent predictor of dialysis-
independent renal function recovery in ESKD patients
[23,24]. The appreciable incidence of renal recovery sug-
gests that caution should be exercised when listing HUS
ESKD patients for renal transplantation within the first
year following dialysis commencement.
Although the overall rate of renal transplantation was
considerably higher in HUS (54%) than in other causes
of ESKD (34%), renal allograft outcomes were signifi-
cantly worse. Compared with non-HUS patients, HUS
patients had significantly inferior overall renal allograft
survival rates at 1 year (73% vs 91%, respectively), 5 years
(62% vs 85%) and 10 years (49% vs 73%). The one-year
first renal allograft survival rates in HUS ESKD patients
were 69% for deceased donor transplants and 79% for
living donor transplants. These findings are appreciably
better than those reported for 78 patients by the
International Registry of Recurrent and Familial HUS/
TTP (32% and 50%, respectively). Part of the apparent
disparity in findings may be potentially explained by HUS
population heterogeneity, vintage bias and ascertainment
bias (since the International HUS/TTP Registry included
data provided by selected, interested global renal units as
well as that obtained from literature searches, whereas the
ANZDATA Registry included all patients with HUS ESKD
who ever received renal replacement therapy in Australia
and New Zealand since 1963). For patients who did not
experience renal allograft failure, possibly reflecting a less
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their non-HUS counterparts.
HUS recurrence occurred in 12% of HUS patients
undergoing renal transplantation after a median period of
0.82 years and accounted for 25 of all renal allograft fail-
ures in patients with HUS ESKD. These findings were
somewhat lower than those of other investigations report-
ing recurrence rates of 25-50% [1,2,12], but may have
related to HUS population heterogeneity (due to inclusion
of patients with typical HUS who had a low risk of post-
transplant recurrence), classification bias due to difficul-
ties in distinguishing HUS recurrence from antibody-
mediated rejection, and possible ascertainment and
reporting bias. In keeping with the findings of other stud-
ies [25], living kidney donation was a significant risk factor
for HUS recurrence in the renal allograft.
The strengths of this study included its very large sam-
ple size and inclusiveness. We included all HUS patients
receiving renal replacement therapy in Australia and New
Zealand during the study period, such that a variety of
centres were included with varying approaches to the
treatment of HUS and ESKD. This greatly enhanced the
external validity of our findings. These strengths should
be balanced against the study’s limitations, which included
limited depth of data collection. ANZDATA does not col-
lect important information, such as distinction between
typical (diarrhoea-associated) and atypical HUS (which
has an important effect on dialysis and transplant out-
comes), date of HUS diagnosis, severity of comorbidities,
patient compliance, individual unit management protocols
(including plasma exchange and eculizumab therapy), la-
boratory values (such as platelet counts, serum lactate de-
hydrogenase concentrations and serum ADAMTS13
measurements) and complement regulatory protein gen-
etic mutation and autoantibody results. Even though we
adjusted for a large number of patient characteristics, the
possibility of residual confounding could not be excluded.
In common with other Registries, ANZDATA is a volun-
tary Registry and there is no external audit of data accur-
acy, including the diagnosis of HUS.Conclusion
In conclusion, HUS is an uncommon cause of ESKD,
which is associated with comparable patient survival
following dialysis or kidney transplantation, and a signifi-
cantly increased probability of dialysis-independent renal
function recovery. Renal transplantation is a safe and ef-
fective therapy for HUS ESKD, although renal allograft
survival rates are worse than for patients with other ESKD
causes. HUS recurrence occurs in 12% of patients and is
the second commonest cause of graft loss in this group
after chronic allograft nephropathy. Caution should be
exercised in transplanting HUS patients within the firstyear of dialysis commencement due to the possibility of
renal function recovery.
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